Why is Vertex Pharmaceuticals stock sliding 4% today?

Vertex Pharmaceuticals experienced a 4.1% drop in mid-day trading, bringing its stock price down to $486.44. The decline was primarily attributed to a recent reduction in BofA Securities' price target, which suggested potential weakness in the company's key revenue generator ahead of its next earnings announcement. BofA Securities lowered its target price from $672 to $667, maintaining its Buy rating, after revising its Q3 model to predict Trikafta revenue of $2.42 billion, which was about 5% lower than the Wall Street consensus estimate.

The bank's report also noted that consensus EPS estimates for the upcoming Q3 report had fallen by approximately 4.5% over the past month, increasing investor caution about near-term results. Vertex is set to release third-quarter financial results on November 2.

On the positive side, Citi analyst Geoff Meacham kept his Buy rating on Vertex with a $585 price target, while the broader analyst community remained supportive, with the average 12-month price target significantly above the current trading level. However, uncertainties surrounding the commercial prospects of newer products like Casgevy and Journavx, coupled with the company's heavy reliance on its cystic fibrosis franchise, have limited enthusiasm.

The broader market did not offer much support, with the Nasdaq down 0.2% and the S&P 500 falling 0.1% due to a semiconductor-led sell-off and investor caution ahead of Wednesday's CPI data release. The convergence of a revised earnings estimate by a major Wall Street firm, rising Treasury yields stressing high-valuation biotech stocks, and a cautious market stance resulted in Vertex trading well below its session open of $507.55, hitting its lowest point in weeks at $486.44 as sellers dominated mid-day trading.